-
★
SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of Immunodeficiency
(Hinzugefügt: 05.08.2023 um 12:09 Uhr)
https://www.medrxiv.org/content/10.1101/2023.07.31.23293441v1
-
★
Rezidivierende SARS-CoV-2-Infektionen bei Immundefizienz
(Hinzugefügt: 30.10.2022 um 09:19 Uhr)
https://link.springer.com/article/10.1007/s00108-022-01424-7
-
★
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses
(Hinzugefügt: 24.06.2022 um 09:43 Uhr)
https://www.cell.com/cancer-cell/fulltext/S1535-6108(22)00226-4
-
★
Anspruch auf COVID-Antikörperprophylaxe neu geregelt
(Hinzugefügt: 05.06.2022 um 15:35 Uhr)
https://www.aerzteblatt.de/nachrichten/134744/Anspruch-auf-COVID-Antikoerperprophylaxe-neu-geregelt
-
★
SARS-CoV-2 evolution and immune escape in immunocompromised patients treated with exogenous antibodies
(Hinzugefügt: 26.04.2022 um 13:42 Uhr)
https://www.medrxiv.org/content/10.1101/2022.04.12.22273675v1
-
★
Préconisations pour protéger les patients de la filière oncologique face au variant OmicronRecommendations to protect patients with cancer against the Omicron variant
(Hinzugefügt: 22.01.2022 um 13:29 Uhr)
https://www.sciencedirect.com/science/article/pii/S0007455121006858
-
★
Researchers Tie Severe Immunosuppression to Chronic COVID-19 and Virus Variants
(Hinzugefügt: 06.05.2021 um 09:15 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2779850?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=050521#.YJM4kz9cbTc.twitter
-
★
SARS-CoV-2 evolution during treatment of chronic infection
(Hinzugefügt: 05.02.2021 um 20:21 Uhr)
https://www.nature.com/articles/s41586-021-03291-y
-
Selective IgA Deficiency May Be an Underrecognized Risk Factor for Severe COVID-19
(Hinzugefügt: 05.08.2023 um 15:26 Uhr)
https://www.sciencedirect.com/science/article/pii/S2213219822010431
-
Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments
(Hinzugefügt: 10.04.2023 um 14:29 Uhr)
https://www.jci.org/articles/view/166032
-
SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
(Hinzugefügt: 10.04.2023 um 14:29 Uhr)
https://www.jci.org/articles/view/168603
-
Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients
(Hinzugefügt: 10.04.2023 um 13:56 Uhr)
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciad181/7091553
-
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
(Hinzugefügt: 07.04.2023 um 17:48 Uhr)
https://www.nature.com/articles/s41467-023-36686-8
-
Persistent SARS-CoV-2 infection in patients seemingly recovered from COVID-19
(Hinzugefügt: 07.04.2023 um 17:41 Uhr)
https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.6035
-
COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada
(Hinzugefügt: 07.04.2023 um 17:31 Uhr)
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(23)00035-2/fulltext?fbclid=IwAR17kpFAD6PPOD-1OEsFefM2Xs8TWwmPB2g4R6PH6XK0vvqbtwdaSLI7RC4
-
SARS-CoV-2 evolves increased infection elicited cell death and fusion in an immunosuppressed individual
(Hinzugefügt: 06.12.2022 um 17:00 Uhr)
https://www.medrxiv.org/content/10.1101/2022.11.23.22282673v2
-
Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review
(Hinzugefügt: 25.11.2022 um 15:52 Uhr)
https://www.sciencedirect.com/science/article/pii/S2590170222000784
-
SARS-CoV-2 evolves increased infection elicited cell death and fusion in an immunosuppressed individual
(Hinzugefügt: 25.11.2022 um 15:52 Uhr)
https://www.medrxiv.org/content/10.1101/2022.11.23.22282673v1
-
SARS-CoV-2 in immunocompromised individuals
(Hinzugefügt: 19.11.2022 um 20:19 Uhr)
https://www.cell.com/immunity/fulltext/S1074-7613(22)00500-3#relatedArticles
-
Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients
(Hinzugefügt: 19.11.2022 um 18:23 Uhr)
https://onlinelibrary.wiley.com/doi/full/10.1111/tid.13967?campaign=wolearlyview
-
Patient cured of Covid after fighting virus for more than 400 days
(Hinzugefügt: 14.11.2022 um 13:16 Uhr)
https://www.manchestereveningnews.co.uk/news/uk-news/patient-cured-covid-after-fighting-25430450
-
«Prolongierter Virusnachweis bei SARS-CoV-2-Infektion unter Immunsuppression»
(Hinzugefügt: 10.11.2022 um 16:00 Uhr)
https://medicalforum.ch/de/detail/doi/smf.2022.09020
-
This Man Had COVID For Over 400 Days. Scientists Explain Why
(Hinzugefügt: 10.11.2022 um 15:59 Uhr)
https://www.sciencealert.com/this-man-had-covid-for-over-400-days-scientists-explain-why
-
Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study
(Hinzugefügt: 17.08.2022 um 10:27 Uhr)
https://www.medrxiv.org/content/10.1101/2022.08.08.22278576v1
-
Intra-host evolution during SARS-CoV-2 prolonged infection
(Hinzugefügt: 24.06.2022 um 09:40 Uhr)
https://academic.oup.com/ve/article/7/2/veab078/6377925
-
How months-long COVID infections could seed dangerous new variants
(Hinzugefügt: 24.06.2022 um 08:05 Uhr)
https://www.nature.com/articles/d41586-022-01613-2
-
Opinion: To Prevent Future Variants, We Must Protect Those Most At Risk
(Hinzugefügt: 24.06.2022 um 08:04 Uhr)
https://undark.org/2022/03/17/to-prevent-future-variants-we-must-protect-immunocompromised/
-
More than a ‘Hundred Days War’: Persistent SARS-CoV-2 infection in a patient with ANCA-associated vasculitis
(Hinzugefügt: 24.06.2022 um 08:03 Uhr)
https://jammi.utpjournals.press/doi/full/10.3138/jammi-2021-0033
-
The association between pre-exposure to glucocorticoids and other immunosuppressant drugs with severe COVID-19 outcomes
(Hinzugefügt: 08.06.2022 um 10:21 Uhr)
https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00270-1/fulltext?dgcid=raven_jbs_aip_email
-
Intrahost evolution and forward transmission of a novel SARS-CoV-2 Omicron BA.1 subvariant
(Hinzugefügt: 06.06.2022 um 09:07 Uhr)
https://www.medrxiv.org/content/10.1101/2022.05.25.22275533v1
-
The COVID-19 Pandemic Rages on for People Who Are Immunocompromised
(Hinzugefügt: 13.05.2022 um 07:39 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2791868
-
Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host
(Hinzugefügt: 13.05.2022 um 07:09 Uhr)
https://www.nature.com/articles/s41467-022-30163-4
-
Persistent SARS-CoV-2 Alpha Variant Infection in Immunosuppressed Patient, France, February 2022
(Hinzugefügt: 09.05.2022 um 09:00 Uhr)
https://wwwnc.cdc.gov/eid/article/28/7/22-0467_article
-
The COVID-19 Pandemic Rages on for People Who Are Immunocompromised
(Hinzugefügt: 30.04.2022 um 11:13 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2791868?resultClick=1
-
Severe COVID-19 represents an undiagnosed primary immunodeficiency in a high proportion of infected individuals
(Hinzugefügt: 26.04.2022 um 13:28 Uhr)
https://onlinelibrary.wiley.com/doi/10.1002/cti2.1365
-
The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet)
(Hinzugefügt: 26.04.2022 um 13:04 Uhr)
https://link.springer.com/article/10.1007/s10875-022-01264-y
-
UK patient had COVID for 505 days
(Hinzugefügt: 26.04.2022 um 12:30 Uhr)
https://www.kcl.ac.uk/news/uk-patient-had-covid-for-505-days
-
Patient über 16 Monate mit SARS-CoV-2 infiziert – auch okkulte Infektion möglich
(Hinzugefügt: 26.04.2022 um 12:28 Uhr)
https://www.aerzteblatt.de/nachrichten/133576/Patient-ueber-16-Monate-mit-SARS-CoV-2-infiziert-auch-okkulte-Infektion-moeglich
-
Longitudinal evolution of SARS-CoV-2 in immunocompromised individuals with persistent infection
(Hinzugefügt: 26.04.2022 um 12:27 Uhr)
https://drive.google.com/file/d/11XHMYIhk-EOxfo_z5AhpFIjY0ieP5Aky/view
-
Longest known COVID-19 infection – 505 days – described by UK researchers
(Hinzugefügt: 26.04.2022 um 12:17 Uhr)
https://www.escmid.org/fileadmin/src/media/PDFs/2News_Discussions/Press_activities/2022/2022-04-21_Longest_known_COVID-19_infection_.pdf
-
Some cases of long COVID-19 may be caused by an abnormally suppressed immune system
(Hinzugefügt: 26.04.2022 um 11:49 Uhr)
https://medicalxpress.com/news/2022-04-cases-covid-abnormally-suppressed-immune.html
-
COVID-19 Clinical Outcomes in Solid Organ Transplant Recipients During the Omicron Surge
(Hinzugefügt: 13.04.2022 um 15:29 Uhr)
https://journals.lww.com/transplantjournal/fulltext/9900/covid_19_clinical_outcomes_in_solid_organ.18.aspx
-
Prolonged SARS-CoV-2 shedding in a person living with advanced HIV and diffuse large B-cell lymphoma: a case report
(Hinzugefügt: 03.04.2022 um 18:00 Uhr)
https://www.tandfonline.com/doi/full/10.1080/23744235.2022.2055136
-
Acute exacerbation of graft-versus-host disease following SARS-CoV2 infection after hematopoietic stem cell transplant in two pediatric patients
(Hinzugefügt: 18.03.2022 um 09:35 Uhr)
https://onlinelibrary.wiley.com/doi/10.1002/pbc.29661
-
Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations
(Hinzugefügt: 18.03.2022 um 09:34 Uhr)
https://www.thelancet.com/action/showPdf?pii=S2666-5247%2822%2900061-1
-
SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity
(Hinzugefügt: 17.03.2022 um 11:07 Uhr)
https://www.frontiersin.org/articles/10.3389/fimmu.2022.840126/full
-
Tacrolimus-resistant SARS-CoV-2-specific T-cell products to prevent and treat severe COVID-19 in immunosuppressed patients
(Hinzugefügt: 11.03.2022 um 11:16 Uhr)
https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(22)00028-6
-
The mutational steps of SARS-CoV-2 to become like Omicron within seven months: the story of immune escape in an immunocompromised patient
(Hinzugefügt: 11.03.2022 um 11:13 Uhr)
https://www.medrxiv.org/content/10.1101/2022.03.04.22271540v1
-
The mutational steps of SARS-CoV-2 to become like Omicron within seven months: the story of immune escape in an immunocompromised patient.
(Hinzugefügt: 08.03.2022 um 10:41 Uhr)
https://www.medrxiv.org/content/10.1101/2022.03.04.22271540v1
-
Recurrent SARS-CoV-2 Mutations in Immunodeficient Patients
(Hinzugefügt: 06.03.2022 um 18:32 Uhr)
https://www.medrxiv.org/content/10.1101/2022.03.02.22271697v1
-
Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection
(Hinzugefügt: 06.03.2022 um 18:30 Uhr)
https://www.nature.com/articles/s41375-021-01175-8
-
Whole-Genome Sequencing of SARS-CoV-2 Infection in a Cluster of Immunocompromised Children in Indonesia
(Hinzugefügt: 06.03.2022 um 18:25 Uhr)
https://www.frontiersin.org/articles/10.3389/fmed.2022.835998/full
-
Vaccinated but Not Protected—Living Immunocompromised During the Pandemic
(Hinzugefügt: 19.02.2022 um 13:26 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2781012
-
Immunocompromised Americans’ Terrifying Reality During COVID
(Hinzugefügt: 17.02.2022 um 07:35 Uhr)
https://www.pbs.org/wnet/amanpour-and-company/video/immunocompromised-americans-terrifying-reality-during-covid/
-
Persistent SARS-CoV-2 Infection with Accumulation of Mutations in a Patient with Poorly Controlled HIV Infection
(Hinzugefügt: 17.02.2022 um 07:04 Uhr)
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4014499
-
Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the United Kingdom
(Hinzugefügt: 17.02.2022 um 06:10 Uhr)
https://academic.oup.com/cei/advance-article/doi/10.1093/cei/uxac008/6515671
-
Individuals with immunodeficiency at high risk of mortality following SARS-CoV-2 infection
(Hinzugefügt: 17.02.2022 um 05:53 Uhr)
https://www.immunology.org/news/individuals-immunodeficiency-high-risk-mortality-following-sars-cov-2-infection
-
Another Variant Emerges From An Immunocompromised Patient
(Hinzugefügt: 24.01.2022 um 20:11 Uhr)
https://www.forbes.com/sites/williamhaseltine/2021/12/21/another-variant-emerges-from-an-immunocompromised-patient/?sh=4fb674b6671c
-
https://www.dailymail.co.uk/health/article-10406071/What-happens-500-000-people-shielding.html
(Hinzugefügt: 22.01.2022 um 13:17 Uhr)
https://www.dailymail.co.uk/health/article-10406071/What-happens-500-000-people-shielding.html
-
Antibody and antiviral treatments for people with blood cancer
(Hinzugefügt: 23.12.2021 um 20:13 Uhr)
https://bloodcancer.org.uk/support-for-you/coronavirus-covid-19/covid-vaccine-blood-cancer/covid-antibody-treatment/
-
Risk of severe coronavirus infection (COVID-19) in patients with inflammatory rheumatic diseases.
(Hinzugefügt: 19.11.2021 um 16:44 Uhr)
https://www.jrheum.org/content/early/2021/03/10/jrheum.200755
-
Kasus: Patientin war über 11 Monate mit SARS-CoV-2 infiziert
(Hinzugefügt: 19.11.2021 um 16:03 Uhr)
https://www.aerzteblatt.de/nachrichten/128340/Kasus-Patientin-war-ueber-11-Monate-mit-SARS-CoV-2-infiziert
-
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative
(Hinzugefügt: 19.11.2021 um 15:26 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00325-8/fulltext
-
Outcomes for hospitalized COVID-19 patients taking immunosuppressive medications similar to non-immunosuppressed patients
(Hinzugefügt: 19.11.2021 um 15:25 Uhr)
https://www.eurekalert.org/news-releases/935179
-
Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants
(Hinzugefügt: 15.11.2021 um 07:36 Uhr)
https://www.nature.com/articles/s41467-021-26602-3
-
Persistent COVID-19 Infection in Wiskott-Aldrich Syndrome Cleared Following Therapeutic Vaccination: a Case Report
(Hinzugefügt: 01.11.2021 um 09:54 Uhr)
https://link.springer.com/article/10.1007/s10875-021-01158-5
-
Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient
(Hinzugefügt: 01.11.2021 um 09:47 Uhr)
https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab553/6414393
-
Clinical characteristics of COVID-19 patients with HIV coinfection in Wuhan, China
(Hinzugefügt: 29.10.2021 um 11:49 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605649/
-
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
(Hinzugefügt: 29.10.2021 um 11:39 Uhr)
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00278-7/fulltext
-
Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion
(Hinzugefügt: 23.10.2021 um 07:19 Uhr)
https://www.medrxiv.org/content/10.1101/2021.10.02.21264267v2
-
Tapering of disease-modifying antirheumatic drugs: an overview for daily practice
(Hinzugefügt: 05.10.2021 um 08:18 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00224-1/fulltext
-
Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies
(Hinzugefügt: 15.09.2021 um 15:34 Uhr)
https://www.medrxiv.org/content/10.1101/2021.08.25.21262417v1
-
SARS-CoV-2 Variants in Patients with Immunosuppression
(Hinzugefügt: 26.08.2021 um 04:11 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMsb2104756
-
COVID-19 Infection, Admission and Death Amongst People with Rare Autoimmune Rheumatic Disease in England. Results from the RECORDER Project
(Hinzugefügt: 24.08.2021 um 16:27 Uhr)
https://www.medrxiv.org/content/10.1101/2021.08.17.21260846v2
-
SARS-CoV-2 Variants in Patients with Immunosuppression
(Hinzugefügt: 06.08.2021 um 11:21 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMsb2104756
-
COVID-19: Serumtherapie kann bei hämatologischen Krebspatienten erfolgreich sein
(Hinzugefügt: 23.06.2021 um 18:01 Uhr)
https://www.aerzteblatt.de/nachrichten/124857/COVID-19-Serumtherapie-kann-bei-haematologischen-Krebspatienten-erfolgreich-sein
-
SARS-CoV-2 shedding, infectivity and evolution in an immunocompromised adult patient
(Hinzugefügt: 20.06.2021 um 17:53 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.11.21257717v1
-
Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’
(Hinzugefügt: 27.05.2021 um 12:04 Uhr)
https://ard.bmj.com/content/early/2021/05/12/annrheumdis-2021-220588
-
Metaanalyse: COVID-19 bei HIV-Infizierten häufiger tödlich
(Hinzugefügt: 15.05.2021 um 10:02 Uhr)
https://www.aerzteblatt.de/nachrichten/123833/Metaanalyse-COVID-19-bei-HIV-Infizierten-haeufiger-toedlich
-
Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient: a source of immune escape variants
(Hinzugefügt: 06.05.2021 um 09:28 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.30.21256244v1
-
SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study
(Hinzugefügt: 30.04.2021 um 05:56 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00112-0/fulltext
-
Relief and worry for immune-suppressed people
(Hinzugefügt: 30.04.2021 um 05:44 Uhr)
https://science.sciencemag.org/content/372/6541/443.full
-
Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment
(Hinzugefügt: 12.04.2021 um 18:09 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.08.21254791v1
-
Innate immune deficiencies in patients with COVID-19
(Hinzugefügt: 01.04.2021 um 05:47 Uhr)
https://www.medrxiv.org/content/10.1101/2021.03.29.21254560v1
-
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
(Hinzugefügt: 27.03.2021 um 04:05 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00059-X/fulltext
-
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
(Hinzugefügt: 26.03.2021 um 08:00 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2777685
-
Risk of severe coronavirus infection (COVID-19) in patients with inflammatory rheumatic diseases
(Hinzugefügt: 17.03.2021 um 02:52 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33722949/
-
Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy
(Hinzugefügt: 17.03.2021 um 02:51 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910130/
-
Corona-Mutationen Das Virus nutzt die Schwachen aus
(Hinzugefügt: 17.03.2021 um 02:08 Uhr)
https://www.spiegel.de/wissenschaft/mensch/corona-menschen-mit-geschwaechtem-immunsystem-sind-offenbar-perfekte-wirte-fuer-das-coronavirus-a-78d1c66f-2b32-4373-b64e-a31cc92a6159
-
SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms
(Hinzugefügt: 17.03.2021 um 01:45 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(21)00355-X
-
Protracted SARS-CoV-2 Pneumonia with Rituximab Treatment: about two cases
(Hinzugefügt: 13.03.2021 um 22:02 Uhr)
https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.26921
-
Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity
(Hinzugefügt: 03.03.2021 um 08:18 Uhr)
https://www.medrxiv.org/content/10.1101/2021.02.27.21252099v1
-
Rheumatologen aktualisieren Empfehlungen zu Therapie und COVID-19-Impfung
(Hinzugefügt: 03.03.2021 um 07:55 Uhr)
https://www.aerzteblatt.de/nachrichten/121656/Rheumatologen-aktualisieren-Empfehlungen-zu-Therapie-und-COVID-19-Impfung
-
Rezeptormangel auf Immunzellen könnte mit schwerem COVID-19-Verlauf verbunden sein
(Hinzugefügt: 24.02.2021 um 16:52 Uhr)
https://www.aerzteblatt.de/nachrichten/121442/Rezeptormangel-auf-Immunzellen-koennte-mit-schwerem-COVID-19-Verlauf-verbunden-sein
-
Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia
(Hinzugefügt: 17.02.2021 um 14:46 Uhr)
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00968-1
-
CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer
(Hinzugefügt: 17.02.2021 um 14:38 Uhr)
https://www.researchsquare.com/article/rs-162289/v1
-
SARS-CoV-2: Bei abwehrgeschwächten Patienten verändert sich das Virus schneller
(Hinzugefügt: 09.02.2021 um 10:03 Uhr)
https://www.aerzteblatt.de/nachrichten/120965/SARS-CoV-2-Bei-abwehrgeschwaechten-Patienten-veraendert-sich-das-Virus-schneller
-
Integrated immune dynamics define correlates of COVID-19 severity and antibody responses
(Hinzugefügt: 06.02.2021 um 09:18 Uhr)
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00019-7
-
COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State
(Hinzugefügt: 04.02.2021 um 09:41 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2775827
-
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study
(Hinzugefügt: 01.02.2021 um 21:25 Uhr)
https://pubmed.ncbi.nlm.nih.gov/32945944/
-
Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up
(Hinzugefügt: 01.02.2021 um 21:24 Uhr)
https://link.springer.com/article/10.1007%2Fs00415-020-10310-x
-
B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?
(Hinzugefügt: 01.02.2021 um 21:17 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30270-8/fulltext
-
B cell memory: understanding COVID-19
(Hinzugefügt: 01.02.2021 um 08:28 Uhr)
https://www.cell.com/immunity/fulltext/S1074-7613(21)00037-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1074761321000376%3Fshowall%3Dtrue
-
Changing COVID-19 outcomes in patients with rheumatic disease—are we really getting better at this?
(Hinzugefügt: 31.01.2021 um 10:31 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00008-4/fulltext
-
Lessons in antiviral immunity
(Hinzugefügt: 29.01.2021 um 09:07 Uhr)
https://science.sciencemag.org/content/371/6528/464.full
-
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
(Hinzugefügt: 28.01.2021 um 18:51 Uhr)
https://ard.bmj.com/content/annrheumdis/early/2021/01/26/annrheumdis-2020-219498.full.pdf
-
Disease modifying therapies and Covid-19 severity in Multiple Sclerosis
(Hinzugefügt: 28.01.2021 um 18:25 Uhr)
https://onlinelibrary.wiley.com/doi/epdf/10.1002/ana.26028
-
Immune response to SARS-CoV-2 in the nasal mucosa in children and adults
(Hinzugefügt: 28.01.2021 um 13:53 Uhr)
https://www.medrxiv.org/content/10.1101/2021.01.26.21250269v1
-
Immunsuppression Rituximab
(Hinzugefügt: 27.01.2021 um 18:01 Uhr)
https://www.ndr.de/nachrichten/info/73-Coronavirus-Update-Dem-Virus-zuvorkommen,podcastcoronavirus282.html#Immunsupprimierte
-
Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients
(Hinzugefügt: 27.01.2021 um 09:37 Uhr)
https://pubmed.ncbi.nlm.nih.gov/32343415/
-
The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient - a case study
(Hinzugefügt: 27.01.2021 um 09:37 Uhr)
https://www.medrxiv.org/content/10.1101/2021.01.23.21249554v1
-
Monoclonal antibodies can prevent COVID-19—but successful vaccines complicate their future
(Hinzugefügt: 23.01.2021 um 09:12 Uhr)
https://www.sciencemag.org/news/2021/01/monoclonal-antibodies-can-prevent-covid-19-successful-vaccines-complicate-their-future
-
Memory B Cells, Infection, and Vaccination
(Hinzugefügt: 22.01.2021 um 08:58 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2021/01/19/memory-b-cells-infection-and-vaccination
-
Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8+ T cells
(Hinzugefügt: 22.01.2021 um 08:56 Uhr)
https://immunology.sciencemag.org/content/6/55/eabe4782.full
-
Early induction of functional SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
(Hinzugefügt: 22.01.2021 um 08:53 Uhr)
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00041-3
-
SARS-CoV-2: Frühe Immunreaktion bestimmt den Verlauf von COVID-19
(Hinzugefügt: 20.01.2021 um 08:26 Uhr)
https://www.aerzteblatt.de/nachrichten/120307/SARS-CoV-2-Fruehe-Immunreaktion-bestimmt-den-Verlauf-von-COVID-19
-
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
(Hinzugefügt: 20.01.2021 um 08:24 Uhr)
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30429-4/fulltext
-
Divergent effects of acute versus chronic glucocorticoids in COVID-19
(Hinzugefügt: 19.01.2021 um 07:10 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00005-9/fulltext
-
Systemische Immunsuppression in Zeiten von COVID‐19: Müssen wir umdenken?
(Hinzugefügt: 17.01.2021 um 20:02 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460968/
-
Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host
(Hinzugefügt: 17.01.2021 um 07:43 Uhr)
https://www.medrxiv.org/content/10.1101/2021.01.10.20248871v1
-
Early immune pathology and persistent dysregulation characterise severe COVID-19
(Hinzugefügt: 16.01.2021 um 08:54 Uhr)
https://www.medrxiv.org/content/10.1101/2021.01.11.20248765v1
-
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study
(Hinzugefügt: 14.01.2021 um 05:04 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00007-2/fulltext
-
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer
(Hinzugefügt: 13.01.2021 um 19:40 Uhr)
https://www.nejm.org/doi/10.1056/NEJMc2031670
-
From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiat
(Hinzugefügt: 12.01.2021 um 08:07 Uhr)
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30392-7/fulltext
-
Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
(Hinzugefügt: 11.01.2021 um 19:24 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v3
-
313 COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality
(Hinzugefügt: 29.12.2020 um 09:31 Uhr)
https://ash.confex.com/ash/2020/webprogram/Paper138611.html
-
Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study
(Hinzugefügt: 26.12.2020 um 10:02 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30422-7/fulltext
-
U.K. variant puts spotlight on immunocompromised patients’ role in the COVID-19 pandemic
(Hinzugefügt: 25.12.2020 um 08:11 Uhr)
https://www.sciencemag.org/news/2020/12/uk-variant-puts-spotlight-immunocompromised-patients-role-covid-19-pandemic
-
Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab
(Hinzugefügt: 20.12.2020 um 09:55 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493633/
-
Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ΔH69/ΔV70
(Hinzugefügt: 18.12.2020 um 10:41 Uhr)
https://www.biorxiv.org/content/10.1101/2020.12.14.422555v2.full.pdf+html
-
Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion
(Hinzugefügt: 18.12.2020 um 10:35 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1
-
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report
(Hinzugefügt: 15.12.2020 um 09:44 Uhr)
https://www.nature.com/articles/s41467-020-19761-2
-
COVID-19: Wie Remdesivir die Infektion bei einem Patienten mit angeborener Immunschwäche beendete
(Hinzugefügt: 15.12.2020 um 09:44 Uhr)
https://www.aerzteblatt.de/nachrichten/119359/COVID-19-Wie-Remdesivir-die-Infektion-bei-einem-Patienten-mit-angeborener-Immunschwaeche-beendete
-
HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform
(Hinzugefügt: 13.12.2020 um 10:46 Uhr)
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30305-2/fulltext
-
Response to: ‘Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroqu
(Hinzugefügt: 28.11.2020 um 12:52 Uhr)
https://ard.bmj.com/content/early/2020/11/24/annrheumdis-2020-218795
-
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic
(Hinzugefügt: 27.11.2020 um 22:09 Uhr)
https://www.jns-journal.com/article/S0022-510X(20)30139-8/fulltext
-
Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up
(Hinzugefügt: 27.11.2020 um 22:07 Uhr)
https://link.springer.com/article/10.1007/s00415-020-10310-x
-
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
(Hinzugefügt: 27.11.2020 um 11:17 Uhr)
https://ard.bmj.com/content/79/5/667
-
Antikörper gegen CD 20: ein Risiko in der Pandemie?
(Hinzugefügt: 23.11.2020 um 16:16 Uhr)
https://link.springer.com/article/10.1007/s15005-020-1512-1
-
Risk Factors for Invasive Pulmonary Aspergillosis in Critically Ill Patients With Coronavirus Disease 2019-Induced Acute Respiratory Distress Syndrome
(Hinzugefügt: 23.11.2020 um 16:10 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665250/
-
Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab
(Hinzugefügt: 16.11.2020 um 12:49 Uhr)
https://www.sciencedirect.com/science/article/pii/S004901722030192X?via%3Dihub
-
Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease
(Hinzugefügt: 16.11.2020 um 12:45 Uhr)
https://link.springer.com/article/10.1007%2Fs00296-020-04715-0
-
Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders
(Hinzugefügt: 16.11.2020 um 12:43 Uhr)
https://onlinelibrary.wiley.com/doi/epdf/10.1111/ene.14612
-
COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases
(Hinzugefügt: 16.11.2020 um 12:38 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405500/
-
Systemische Immunsuppression in Zeiten von COVID‐19: Müssen wir umdenken?
(Hinzugefügt: 12.11.2020 um 20:28 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460968/
-
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
(Hinzugefügt: 12.11.2020 um 17:55 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2031364
-
Lymphopenie
(Hinzugefügt: 04.11.2020 um 19:16 Uhr)
https://www.biorxiv.org/content/10.1101/2020.08.04.236521v1
-
Compromised humoral functional evolution tracks with SARS-CoV-2 mortality
(Hinzugefügt: 03.11.2020 um 20:08 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(20)31459-8
-
A dynamic COVID-19 immune signature includes associations with poor prognosis
(Hinzugefügt: 03.11.2020 um 19:44 Uhr)
https://www.nature.com/articles/s41591-020-1038-6
-
B cells and T cells mediate immunity to COVID-19
(Hinzugefügt: 03.11.2020 um 15:20 Uhr)
https://www.nature.com/articles/s41577-020-00436-4
-
Age-specific mortality and immunity patterns
(Hinzugefügt: 02.11.2020 um 18:38 Uhr)
https://www.nature.com/articles/s41586-020-2918-0
-
Organtransplantation
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://link.springer.com/article/10.1007/s40472-020-00307-w
-
BZell Mangel
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://ashpublications.org/blood/article/doi/10.1182/blood.2020008423/463806/Convalescent-plasma-therapy-for-B-cell-depleted
-
immunocompomises patient
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.medrxiv.org/content/10.1101/2020.09.20.20196899v1
-
Lymphozytopenie
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.medrxiv.org/content/10.1101/2020.10.02.20200931v1
-
Immunsystem
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.sciencedirect.com/science/article/pii/S0042682220301720
-
"Coronavirus-Infektion (COVID-19) bei Patienten mit Blut- und Krebserkrankungen"
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.awmf.org/leitlinien/detail/ll/018-037.html
-
Bzell Mangel
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://ashpublications.org/blood/article/doi/10.1182/blood.2020008423/463806/Convalescent-plasma-therapy-for-B-cell-depleted
-
Interferon
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2020/09/28/interferon-and-the-coronavirus
-
Prolonged SARS-CoV-2 replication
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa666/5934826
-
Antibodies IFN
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://science.sciencemag.org/content/370/6515/eabd4585.full
-
TZellen
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.nature.com/articles/s41590-020-0798-y
-
TZellen
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.aerzteblatt.de/nachrichten/116178/T-Helferzellen-bei-COVID-19-Risikopatienten-ausgebremst
-
Lymphozyten
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.cell.com/immunity/fulltext/S1074-7613(20)30333-2
-
Lymphopenia
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.biorxiv.org/content/10.1101/2020.08.04.236521v1
-
Rituximab
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30270-8/fulltext
-
Leukozyten
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.frontiersin.org/articles/10.3389/fpubh.2020.00299/full
-
false negatives
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.nature.com/articles/s41409-020-0972-8
-
Rituximab
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://ard.bmj.com/content/early/2020/06/05/annrheumdis-2020-217955
-
Rolle des Immunsystems
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.aerzteblatt.de/archiv/216372/Infektion-mit-SARS-CoV-2-Abwehr-im-Ausnahmezustand
-
TZellen
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(20)31235-6
-
TZellen
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://immunology.sciencemag.org/content/5/49/eabd6160.full
-
SARS-CoV-2 in rituximab-treated
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://link.springer.com/article/10.1007/s00415-020-10046-8